Seek Returns logo

NVO vs. RVTY: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at NVO and RVTY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

NVO trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, RVTY is a standard domestic listing.

SymbolNVORVTY
Company NameNovo Nordisk A/SRevvity, Inc.
CountryDenmarkUnited States
GICS SectorHealth CareHealth Care
GICS IndustryPharmaceuticalsLife Sciences Tools & Services
Market Capitalization266.59 billion USD10.65 billion USD
ExchangeNYSENYSE
Listing DateApril 30, 1981February 21, 1973
Security TypeADRCommon Stock

Historical Performance

This chart compares the performance of NVO and RVTY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

NVO vs. RVTY: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolNVORVTY
5-Day Price Return2.50%0.34%
13-Week Price Return-15.20%-8.35%
26-Week Price Return-20.75%-8.91%
52-Week Price Return67.26%-25.10%
Month-to-Date Return9.01%4.70%
Year-to-Date Return-39.81%-17.78%
10-Day Avg. Volume5.77M1.13M
3-Month Avg. Volume6.56M1.24M
3-Month Volatility63.71%40.91%
Beta1.551.06

Profitability

Return on Equity (TTM)

NVO

77.86%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.85%
Q1
5.40%
Min
-10.91%

NVO’s Return on Equity of 77.86% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

RVTY

3.71%

Life Sciences Tools & Services Industry

Max
19.96%
Q3
11.51%
Median
6.47%
Q1
3.86%
Min
-6.95%

RVTY’s Return on Equity of 3.71% is in the lower quartile for the Life Sciences Tools & Services industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.

NVO vs. RVTY: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Net Profit Margin (TTM)

NVO

35.61%

Pharmaceuticals Industry

Max
40.67%
Q3
19.07%
Median
12.31%
Q1
4.50%
Min
-9.91%

A Net Profit Margin of 35.61% places NVO in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

RVTY

10.19%

Life Sciences Tools & Services Industry

Max
32.18%
Q3
18.30%
Median
10.19%
Q1
4.20%
Min
-2.05%

RVTY’s Net Profit Margin of 10.19% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.

NVO vs. RVTY: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Operating Profit Margin (TTM)

NVO

45.78%

Pharmaceuticals Industry

Max
45.78%
Q3
23.14%
Median
16.68%
Q1
7.98%
Min
-7.13%

An Operating Profit Margin of 45.78% places NVO in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

RVTY

13.57%

Life Sciences Tools & Services Industry

Max
38.39%
Q3
21.40%
Median
13.57%
Q1
8.38%
Min
-3.51%

RVTY’s Operating Profit Margin of 13.57% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.

NVO vs. RVTY: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Profitability at a Glance

SymbolNVORVTY
Return on Equity (TTM)77.86%3.71%
Return on Assets (TTM)24.22%2.29%
Net Profit Margin (TTM)35.61%10.19%
Operating Profit Margin (TTM)45.78%13.57%
Gross Profit Margin (TTM)83.95%55.93%

Financial Strength

Current Ratio (MRQ)

NVO

0.78

Pharmaceuticals Industry

Max
4.65
Q3
2.64
Median
1.85
Q1
1.26
Min
0.78

NVO’s Current Ratio of 0.78 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

RVTY

3.33

Life Sciences Tools & Services Industry

Max
3.46
Q3
2.78
Median
1.91
Q1
1.53
Min
0.43

RVTY’s Current Ratio of 3.33 is in the upper quartile for the Life Sciences Tools & Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.

NVO vs. RVTY: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

NVO

0.59

Pharmaceuticals Industry

Max
1.75
Q3
0.82
Median
0.35
Q1
0.13
Min
0.00

NVO’s Debt-to-Equity Ratio of 0.59 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

RVTY

0.43

Life Sciences Tools & Services Industry

Max
1.35
Q3
0.74
Median
0.41
Q1
0.18
Min
0.00

RVTY’s Debt-to-Equity Ratio of 0.43 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

NVO vs. RVTY: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Interest Coverage Ratio (TTM)

NVO

149.07

Pharmaceuticals Industry

Max
103.95
Q3
43.60
Median
9.83
Q1
2.37
Min
-42.71

With an Interest Coverage Ratio of 149.07, NVO demonstrates a superior capacity to service its debt, placing it well above the typical range for the Pharmaceuticals industry. This stems from either robust earnings or a conservative debt load.

RVTY

15.30

Life Sciences Tools & Services Industry

Max
45.00
Q3
27.84
Median
7.16
Q1
2.12
Min
-14.08

RVTY’s Interest Coverage Ratio of 15.30 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.

NVO vs. RVTY: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Financial Strength at a Glance

SymbolNVORVTY
Current Ratio (MRQ)0.783.33
Quick Ratio (MRQ)0.562.75
Debt-to-Equity Ratio (MRQ)0.590.43
Interest Coverage Ratio (TTM)149.0715.30

Growth

Revenue Growth

NVO vs. RVTY: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

NVO vs. RVTY: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

NVO

3.06%

Pharmaceuticals Industry

Max
7.14%
Q3
3.45%
Median
2.17%
Q1
0.33%
Min
0.00%

NVO’s Dividend Yield of 3.06% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

RVTY

0.32%

Life Sciences Tools & Services Industry

Max
1.41%
Q3
0.65%
Median
0.35%
Q1
0.00%
Min
0.00%

RVTY’s Dividend Yield of 0.32% is consistent with its peers in the Life Sciences Tools & Services industry, providing a dividend return that is standard for its sector.

NVO vs. RVTY: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Dividend Payout Ratio (TTM)

NVO

61.60%

Pharmaceuticals Industry

Max
199.58%
Q3
97.17%
Median
53.47%
Q1
22.97%
Min
0.00%

NVO’s Dividend Payout Ratio of 61.60% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

RVTY

11.88%

Life Sciences Tools & Services Industry

Max
113.14%
Q3
61.34%
Median
17.74%
Q1
0.00%
Min
0.00%

RVTY’s Dividend Payout Ratio of 11.88% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

NVO vs. RVTY: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Dividend at a Glance

SymbolNVORVTY
Dividend Yield (TTM)3.06%0.32%
Dividend Payout Ratio (TTM)61.60%11.88%

Valuation

Price-to-Earnings Ratio (TTM)

NVO

15.02

Pharmaceuticals Industry

Max
45.19
Q3
27.91
Median
20.59
Q1
15.08
Min
3.79

In the lower quartile for the Pharmaceuticals industry, NVO’s P/E Ratio of 15.02 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

RVTY

37.44

Life Sciences Tools & Services Industry

Max
75.35
Q3
51.00
Median
32.93
Q1
25.27
Min
1.43

RVTY’s P/E Ratio of 37.44 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

NVO vs. RVTY: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Price-to-Sales Ratio (TTM)

NVO

5.35

Pharmaceuticals Industry

Max
8.87
Q3
4.56
Median
2.14
Q1
1.58
Min
0.11

NVO’s P/S Ratio of 5.35 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

RVTY

3.82

Life Sciences Tools & Services Industry

Max
10.49
Q3
6.43
Median
4.66
Q1
2.88
Min
1.08

RVTY’s P/S Ratio of 3.82 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

NVO vs. RVTY: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Price-to-Book Ratio (MRQ)

NVO

8.87

Pharmaceuticals Industry

Max
9.78
Q3
4.99
Median
2.48
Q1
1.53
Min
0.59

NVO’s P/B Ratio of 8.87 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

RVTY

1.51

Life Sciences Tools & Services Industry

Max
6.69
Q3
5.00
Median
3.46
Q1
2.38
Min
0.93

RVTY’s P/B Ratio of 1.51 is in the lower quartile for the Life Sciences Tools & Services industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

NVO vs. RVTY: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Valuation at a Glance

SymbolNVORVTY
Price-to-Earnings Ratio (TTM)15.0237.44
Price-to-Sales Ratio (TTM)5.353.82
Price-to-Book Ratio (MRQ)8.871.51
Price-to-Free Cash Flow Ratio (TTM)25.3221.23